UNV Medicine Ltd. signed a memorandum of understanding to acquire D-Pharm LTD. (TASE:DPRM) in a reverse merger transaction on March 28, 2018. UNV Medicine Ltd. signed a merger deal to acquire D-Pharm LTD. on May 9, 2018. The deal will be conducted by way of a share swap, without cash involved, in such a way that the shareholders of the UNV will transfer to the D-Pharm their full holdings in the shares of the UNV on a fully diluted basis, and in consideration for which D-Pharm will allot to the shareholders of UNV on the closing date of the transaction a number of ordinary shares, representing 48% of D-Pharm's issued and paid up share capital fully diluted. Following completion, UNV’s shareholders and Eli Cohen (Chairman of the Board of Directors of D-Pharm) together will hold 51% of D-Pharm. The deal is subject to a number of suspending conditions including UNV Medicine’s deficit not being above ILS 0.5 million and its coffers shall have ILS 5 million, UNV Medicine’s shareholders being entitled to appoint three Directors to the Board while interested parties being entitled to appoint two Directors to the Board of D-Pharm and D-Pharm providing UNV Medicine with a loan of up to ILS 1 million. The Board of Directors of D-Pharm has approved the deal. As of August 14, 2018, the transaction was approved by the shareholders of D-Pharm LTD. Moti Dattelkramer of BDO acted as accountant to D Pharma LTD. UNV Medicine Ltd. completed the acquisition of D-Pharm LTD. (TASE:DPRM) in a reverse merger transaction on September 6, 2018. In exchange for UNV Medicine's shares, D-Pharm has allocated 7.8 million ordinary shares to all shareholders of UNV Medicine.